CD8A and neoplasm: In preclinical models, CD8+ TILs are cytotoxic against allogeneic tumor cells (Théoleyre et al, 2005), and the number of CD8+ or CD8+/TIA1+ TILs correlates positively with longer survival in patients (van Erp et al, 2017; Gomez‐Brouchet et al, 2017; Palmerini et al, 2017).